Discovery to Diagnostics Whitepaper Part 2

Neurological disorders impact an estimated one billion individuals globally, causing significant long-term disabilities and claiming an estimated nine million lives each year(1). Despite notable advancements in promising new therapeutics, early and accurate diagnosis remains paramount to optimizing treatment response and slowing neurodegeneration and disease progression.

Recent strides in neurological research have highlighted the critical role of biomarkers. Biomarkers serve as indicators of normal biological processes, pathogenic processes, or biological responses to an exposure or intervention(2) and are emerging as pivotal tools in clinical research and healthcare. Numerous studies have underscored their potential in drug development, diagnosis, prognosis, monitoring, and precision medicine. However, thorough validation is paramount for the adoption of these biomarkers in clinical settings. Download our whitepaper to learn more.

1.    Feigin VL, Vos T, Nichols E, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neural. 2020;19(3):255-265. doi:10.1016/S1474-4422(19)30411-9 

2.    FDA-NIH Biomarker Working Group. BEST (Biomarkers, Endpoints, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016-. Glossary. 2076 Jan 28 [Updated 2021 Nov 29]. Available from: ncbi.nlm.nih.gov/books/NBK338448/